tbuckley/cabot-search huggingface dataset:
Endogenous Nitric Oxide Synthesis Inhibitor Asymmetrical Dimethyl-L-Arginine (ADMA) and Neoplasms in Children
Authors: Adrian Doroszko, Ewa Niedzielska, Dorota Wojcik, Elzbieta Wojcik, Andrzej Szuba, Ryszard Andrzejak
Journal: Blood (2008)
RBC Adhesive Capacity Is Essential for Efficient 'Immune Adherence Clearance' and Provide a Generic Target to Deplete Pathogens from Septic Patients
Authors: Djuna Zoe De Back, Elena Kostova, Thomas Klei, Boukje Beuger, Rob van Zwieten, Taco Kuijpers, Nicole Juffermans, Timo van den Berg, Dirk Korte, Marian van Kraaij, Robin van Bruggen
Journal: Blood (2016)
Abstract P2-07-13: <i>TP53</i> gene polymorphisms (c.[215G&amp;gt;C]) in breast cancer patients and predisposition to family cancers- Single center experience
Authors: J Huszno, E Grzybowska, M Nycz Bochenek, J Pamula Pilat, K Tecza, E Nowara
Journal: Cancer Research (2017)

Abstract Introduction: Somatic mutations in the TP53 gene are one of the most frequent alterations in human cancers, and germline mutations are the underlying cause of Li-Fraumeni syndrome, which predisposes to a wide spectrum of early-onset cancers. The aim of this study was to evaluate the association between TP53 gene polymorphisms (c.[215G&amp;gt;C]) and predisposition to family cancers. Methods: We reviewed the medical records of 89 (21% TP53 gene homozygotes and 79% heterozygotes) breast cancer patients who were diagnosed and treated in COI in Gliwice. The history of family cancers was colected from medical history. Mutation profile was assessed by RFLP-PCR technique. We evaluatedthe presence ofpolymorphism TP53 (c.[215G&amp;gt;C]). Statistical analysis was carried out using STATISTICA 7 software. Results: Cancers in family history were detected in 72% of pts with TP53 polymorphisms and they were observed insignificantly more often in heterozygotes than in homozygotes (76% vs. 58%, p=0.153). The most frequently reported cancers were: breast cancer (33%), lymphoma (17%), colorectal cancer (9%), OUN cancer (8%), gastric cancer (8%), pancreatic cancer (7%), ovarian cancer (6%) and renal cancer (3%). In analyzed group, renal cancers in family were detected more frequently in TP53 homozygotes than in heterozygotes (16% vs. 0, p=0.008). Similarly, there was also observed tendency to the presence of colorectal cancer in TP53 homozygotes (11% vs. 0, p=0.193). Ovarian cancers and cholangiocarcinomas in family were also observed insignificantly more often in homozygotes than in heterozygotes (7% vs. 0, p=0.580) and (5% vs. 1%, p=0.383). There was no association between number of cancers in family and TP53 polymorphisms (47% vs. 43%, p=0.797). Conclusion: TP53 polymorphism (c.[215G&amp;gt;C]) predisposed to development renal and colorectal cancers (TP53 homozygotes) and ovarian cancer or cholangiocarcinoma (TP53 heterozygotes) in family. Citation Format: Huszno J, Grzybowska E, Nycz Bochenek M, Pamula Pilat J, Tecza K, Nowara E. TP53 gene polymorphisms (c.[215G&amp;gt;C]) in breast cancer patients and predisposition to family cancers- Single center experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-07-13.
Abstract P3-05-09: Glucocorticoid receptor modulation affects ER+ breast cancer cell proliferation
Authors: E Tonsing-Carter, KR Bowie, DC West, RV Harkless, KM Hernandez, SD Conzen
Journal: Cancer Research (2017)

Abstract Early-stage ER+ breast cancer with high tumor glucocorticoid receptor (GR) expression is associated with improved long term relapse-free survival compared to tumors with low GR expression. In addition, activation of GR inhibits estradiol-mediated ER+ BC cell proliferation. This finding led us to hypothesize that GR and ER engage in nuclear receptor cross-talk to affect pro-proliferative gene expression, thus contributing to a better outcome in ER+/GR+ BC patients. To better understand the mechanisms by which ER/GR co-activation contributes to this more indolent phenotype, we performed ChIP-sequencing and gene expression analyses in ER+/GR+ BC cell lines (MCF-7 and T47D). We found that co-activation of ER and GR led to decreased ER+ BC cell proliferation in vitro. Furthermore, following co-activation of ER/GR, there was decreased gene expression of key cell cycle genes (e.g. CDK6, CDK2 and CCNE1) compared to ER-activation alone. Studies are underway to determine if this decrease in gene expression is associated with less CDK activity as well as a slowing of cell cycle progression. We also wanted to know if GR activation with a pure agonist versus a mixed GR modulator was required for decreasing ER-mediated cell proliferation. Based on our previous work (DC West et al. MCR 2016), we hypothesized that ligand-mediated GR activation could be working by preventing access of ER to regulatory regions of pro-proliferative genes rather than causing direct GR agonist-mediated gene expression. To examine this question, we used a GR modulator, mifepristone (expected to alter ER-mediated gene expression indirectly). Indeed we found that a GR modulator also reduced ER-mediated cell proliferation. We are currently testing the mechanisms by which GR modulators affect estradiol-mediated cell cycle gene expression. Taken together, these studies suggest that modulation of GR activity could be an effective approach to decrease ER+ tumor cell proliferation. Xenograft studies are underway to examine whether the addition of GR modulation to tamoxifen will improve tumor shrinkage compared to tamoxifen alone. Citation Format: Tonsing-Carter E, Bowie KR, West DC, Harkless RV, Hernandez KM, Conzen SD. Glucocorticoid receptor modulation affects ER+ breast cancer cell proliferation [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-05-09.
Mutations of the PTPN11 Gene in Childhood Hematological Malignancies.
Authors: Yuyan Chen, Junko Takita, Mitsuteru Hiwatari, Ryoji Hanada, Akira Kikuchi, Masahiro Tsuchida, Kenichi Sugita, Masahiro Sako, Tomohiko Taki, Mizuho Ogasawara, Yasuhide Hayashi
Journal: Blood (2004)
Differences in Transfusion-Related Alloimmunity to Erythrocytes Between South Korea and Japan; Recent Results from the Third Cooperative International Study of Alloimmunity to Antigen Diversity in Asian Populations
Authors: Akihiro Takeshita, Miwa Adachi, Dae Won Kim, Kyou Sup Han, So Yong Kwon, Hyun Ok Kim, Jang Soo Suh, Hiroko Watanabe, Makoto Uchikawa, Yutaka Tomoda, Kimiko Yurugi, Shuichi Kino, Hitoshi Ohto
Journal: Blood (2014)
Erythropoietin Signaling Regulates Heme Biosynthesis
Authors: Jacky Chung, Johannes G. Wittig, Alireza Ghamari, Manami Maeda, Harvey Lodish, Daniel E. Bauer, Stuart H. Orkin, Alan B. Cantor, Takahiro Maeda, Harry A. Dailey, Barry H. Paw
Journal: Blood (2016)
Wide Complex Tachycardia on Telemetry
Authors: Santosh K. Padala, Gautham Kalahasty, Kenneth A. Ellenbogen
Journal: Circulation (2017)

ECG CHALLENGEA 76-year-old woman with a history of hypertension, diabetes mellitus, dilated nonischemic cardiomyopathy (ejection fraction of 35%), and normal pressure hydrocephalus for which she had received a ventriculoperitoneal shunt 5 years ago was found unresponsive at home.She was intubated for airway protection in the field and was admitted to an outside hospital where an extensive neurological workup did not reveal the cause of her unconsciousness.She was transferred to our hospital to evaluate a potential cardiac etiology for her symptoms.On admission, she was noted to have an incessant wide complex tachycardia at a rate of ≈230 beats per minute on telemetry (Figure 1A and 1B).What is the most likely diagnosis, and what is the cause for the intermittent pauses during tachycardia?Please turn the page to read the diagnosis.
A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity
Authors: Inge Ubink, Sjoerd G. Elias, Cathy B. Moelans, Miangela M. Laclé, Wilhelmina M. U. van Grevenstein, Paul J. van Diest, Inne H. M. Borel Rinkes, Onno Kranenburg
Journal: JNCI Journal of the National Cancer Institute (2016)

Consensus molecular subtype 4 (CMS4) is a recently identified aggressive colon cancer subtype for which platelet-derived growth factor receptors (PDGFRs) and KIT are potential therapeutic targets. We aimed to develop a clinically applicable CMS4 reverse transcription polymerase chain reaction (RT-qPCR) test to select patients for PDGFR/KIT-targeted therapy.We used logistic regression to develop a CMS4 prediction rule based on microarray expression values of PDGFRA , PDGFRB , PDGFC , and KIT (566 training and 1259 test samples, using the 273-gene random forest classifier as CMS4 reference standard). We next translated the prediction rule into a single-sample RT-qPCR test, which we independently validated in 29 fresh tumor samples. To study intratumor CMS4 heterogeneity, we used the RT-qPCR test to analyze five random regions of 20 colon tumors.The microarray-based prediction rule diagnosed CMS4-type tumors extremely well in both training and independent test samples (training: area under the curve [AUC] = 0.95, 95% confidence interval [CI] = 0.94 to 0.97; test: AUC = 0.95, 95% CI = 0.94 to 0.96), with excellent calibration and approximately 80% overall net benefit over a large threshold range. Translation into an RT-qPCR test did not affect discrimination (AUC = 0.97, 95% CI = 0.93 to 1.00, independent validation). RT-qPCR analysis of five random tumor regions revealed extensive intratumor CMS4 heterogeneity in nine out of 20 tumors. At least two regions likely have to be analyzed to identify patients that are predominantly CMS4 positive (>50% average CMS4 chance).The CMS4 RT-qPCR test is a promising clinical tool for selecting individual patients for CMS4-subtype-targeted therapy.
A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure
Authors: Gordon R Reeves, David J Whellan, Christopher M O'Connor, Pamela Duncan, Joel D Eggebeen, Timothy M Morgan, Leigh Ann Hewston, Amy Pastva, Mahesh J Patel, Dalane W Kitzman
Journal: JACC Heart Failure (2017)
Outcome After First Relapse In Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Authors: Shinichi Kako, Heiwa Kanamori, Naoki Kobayashi, Akio Shigematsu, Yasuhito Nannya, Mika Nakamae, Kazuyuki Shigeno, Kazumi Suzukawa, Masahiro Takeuchi, Motohiro Tsuzuki, Kensuke Usuki, Kazuo Hatanaka, Kazuei Ogawa, Kinuko Mitani, Yuichiro Nawa, Yoshihiro Hatta, Ishikazu Mizuno, Yoshinobu Kanda
Journal: Blood (2011)
BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo
Authors: Susanne Hipp, Petra Deegen, Joachim Wahl, Diann Blanset, Oliver Thomas, Benno Rattel, Paul Adam, Matthias Friedrich
Journal: Blood (2015)
Physiological and clinical relevance of exercise ventilatory efficiency in COPD
Authors: J. Alberto Neder, Danilo C. Berton, Flavio F. Arbex, Maria Clara Alencar, Alcides Rocha, Priscila A. Sperandio, Paolo Palange, Denis E. O'Donnell
Journal: European Respiratory Journal (2017)

Exercise ventilation ( V ′ E ) relative to carbon dioxide output ( V ′ CO 2 ) is particularly relevant to patients limited by the respiratory system, e.g. those with chronic obstructive pulmonary disease (COPD). High V ′ E − V ′ CO 2 (poor ventilatory efficiency) has been found to be a key physiological abnormality in symptomatic patients with largely preserved forced expiratory volume in 1 s (FEV 1 ). Establishing an association between high V ′ E − V ′ CO 2 and exertional dyspnoea in mild COPD provides evidence that exercise intolerance is not a mere consequence of detraining. As the disease evolves, poor ventilatory efficiency might help explaining “out-of-proportion” breathlessness (to FEV 1 impairment). Regardless, disease severity, cardiocirculatory co-morbidities such as heart failure and pulmonary hypertension have been found to increase V ′ E − V ′ CO 2 . In fact, a high V ′ E − V ′ CO 2 has been found to be a powerful predictor of poor outcome in lung resection surgery. Moreover, a high V ′ E − V ′ CO 2 has added value to resting lung hyperinflation in predicting all-cause and respiratory mortality across the spectrum of COPD severity. Documenting improved ventilatory efficiency after lung transplantation and lung volume reduction surgery provides objective evidence of treatment efficacy. Considering the usefulness of exercise ventilatory efficiency in different clinical scenarios, the V ′ E − V ′ CO 2 relationship should be valued in the interpretation of cardiopulmonary exercise tests in patients with mild-to-end-stage COPD.
Phase I Trial of Multiple Infusions of Autologous Activated T Cells with Anti-CD3 x Anti-CD20 Bispecific Antibody (CD20Bi) after Autologous Peripheral Blood Stem Cell Transplant for NonHodgkins Lymphoma To Improve Graft-vs-Lymphoma Effects.
Authors: Lawrence G. Lum, Joseph P. Uberti, Zaid Al-Kadhimi, Cassara Skuba, Pat Steele, Rebecca Sandborg, Voravit Ratanatharathorn
Journal: Blood (2007)
Trends in the Use of Moderate-Intensity to High-Intensity Statin and Nonstatin Lipid-Lowering Therapy: Turning Off the Faucet Is Much More Valuable Than Mopping Up the Floor
Authors: Roger S. Blumenthal, Ty J. Gluckman, Seth S. Martin
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
The EuroChimerism Concept for a Standardized Approach to Chimerism Analysis Following Allogeneic Stem Cell Transplantation.
Authors: Thomas Lion, Marcel Tilanus, Hélène Cavé, Mark Lawler, Anna Serra, Andrea Biondi, Jacques van Dongen, Marcos González, Gisela Barbany, Eddy Roosnek, Colin Steward, Peter Bader
Journal: Blood (2006)
Risk of Venous Thromboembolism in Relatives of Factor V Leiden and Factor II G20210A Carriers: A Combined Analysis of Retrospective and Prospective Studies.
Authors: Luciana C.O. Oliveira, Edgar G. Rizzatti, Rosemeire A.S. Inacio, Marcia S. Baggio, Marli H. Tavella, Rendrik F. Franco
Journal: Blood (2005)
Abstract IA28: Molecular pathological epidemiology of risk factors and CRC microbial and immune characteristics
Authors: Shuji Ogino
Journal: Cancer Research (2017)

Abstract Innate and adaptive immunity plays an important role during carcinogenesis and tumor evolution. Evidence indicates that modifiable factors such as aspirin use, physical activity, obesity, smoking, alcohol, diet, and gut microbiota can influence not only cancer risk and outcome but also the human immune system. In addition, tumor molecular pathology and immunity influence each other. Over the past years, molecular pathology and epidemiology has been united to develop the integrative field of molecular pathological epidemiology (MPE). Recently, we have further integrated cancer immunology and MPE, into a new model of “immuno-MPE”. Immuno-MPE utilizes the MPE research framework to test statistical heterogeneity of the differential associations with tumor subtypes, and can decipher the relations between risk factors and subtypes classified by immune response status. We conducted proof-of-principle studies utilizing two large U.S.-nationwide prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study). We have shown that plasma vitamin D level (Song M et al. Gut 2016), germline genetic variation (IBD risk allele rs11676348) (Khalili H et al. Carcinogenesis 2015), and marine omega-3 polyunsaturated fatty acid intake (Song M et al. JAMA Oncology 2016) are associated with altered risk of specific immune subtypes of colorectal carcinoma. We have also shown that tumor neoantigen loads (Giannakis M et al. Cell Reports 2016), CD274 (PD-L1) expression (Masugi Y et al. Gut 2016), and Fusobacterium nucleatum (Mima K et al. JAMA Oncology 2015) are associated with densities of CD3+, CD8+, CD45RO+, or FOXP3+ T cells or lymphocytic response (eg., Crohn's-like lymphoid reaction, tumor-infiltrating lymphocytes, TILs) in rectal and colon cancer. Recently, we have shown that certain dietary patterns are associated with altered risk of colorectal cancer enriched with F. nucleatum, suggesting interactive carcinogenic roles of food, nutrients, and microflora (microbiome). The immuno-MPE approach can integrate tumor and immune data together with exposure risk factors and outcome. Immuno-MPE can not only give insights on how risk factors can interact with the immune system to modify cancer incidence, recurrence and survival, but also help develop strategies of immunoprevention and immunotherapy for precision medicine. Citation Format: Shuji Ogino. Molecular pathological epidemiology of risk factors and CRC microbial and immune characteristics. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr IA28.
Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells
Authors: Ying Wan, Fanyin Meng, Nan Wu, Tianhao Zhou, Julie Venter, Heather Francis, Lindsey Kennedy, Trenton Glaser, Francesca Bernuzzi, Pietro Invernizzi, Shannon Glaser, Qiaobing Huang, Gianfranco Alpini
Journal: Hepatology (2017)

Substance P (SP) is involved in the proliferation of cholangiocytes in bile duct–ligated (BDL) mice and human cholangiocarcinoma growth by interacting with the neurokinin‐1 receptor (NK‐1R). To identify whether SP regulates liver fibrosis during cholestasis, wild‐type or NK‐1R knockout (NK‐1R –/– ) mice that received BDL or sham surgery and multidrug resistance protein 2 knockout ( Mdr2 –/– ) mice treated with either an NK‐1R antagonist (L‐733,060) or saline were used. Additionally, wild‐type mice were treated with SP or saline intraperitoneally. In vivo , there was increased expression of tachykinin precursor 1 (coding SP) and NK‐1R in both BDL and Mdr2 –/– mice compared to wild‐type mice. Expression of tachykinin precursor 1 and NK‐1R was significantly higher in liver samples from primary sclerosing cholangitis patients compared to healthy controls. Knockout of NK‐1R decreased BDL‐induced liver fibrosis, and treatment with L‐733,060 resulted in decreased liver fibrosis in Mdr2 –/– mice, which was shown by decreased sirius red staining, fibrosis gene and protein expression, and reduced transforming growth factor‐β1 levels in serum and cholangiocyte supernatants. Furthermore, we observed that reduced liver fibrosis in NK‐1R –/– mice with BDL surgery or Mdr2 –/– mice treated with L‐733,060 was associated with enhanced cellular senescence of hepatic stellate cells and decreased senescence of cholangiocytes. In vitro , L‐733,060 inhibited SP‐induced expression of fibrotic genes in hepatic stellate cells and cholangiocytes; treatment with L‐733,060 partially reversed the SP‐induced decrease of senescence gene expression in cultured hepatic stellate cells and the SP‐induced increase of senescence‐related gene expression in cultured cholangiocytes. Conclusion : Collectively, our results demonstrate the regulatory effects of the SP/NK‐1R axis on liver fibrosis through changes in cellular senescence during cholestatic liver injury. (H epatology 2017;66:528–541).
Comparable Toxicity between Fludarabine/Full dose i.v. Busulfan and Fludarabine/Melphalan in Allogeneic PBSC Transplantation.
Authors: Sandeep Chunduri, Ellen Jessop, Lisa C. Dobogai, David Peace, Yogen Sanuthararajah, Yi-Hsiang Chen, Nadim Mahmud, Vera Maynard, Ronald Hoffman, Damiano Rondelli
Journal: Blood (2004)
Reconfiguring the Hospital-to-Home Transition Into an Active Treatment Period for Patients With Heart Failure
Authors: Tien M. H. Ng, Rishi Menon, Paul J. Hauptman
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment
Authors: Katja Weisel, Meletios A Dimopoulos, Niels W.C.J. van de Donk, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld
Journal: Blood (2016)
Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.
Authors: Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou
Journal: Blood (2009)